Athira Pharma, Inc. — Director's Dealing 2023

Feb 1, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2023-01-27

Reporting Person: Litton Mark James (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-18	Common Stock	A	662	$2.74	Acquired	129217	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-27	Stock Option (Right to Buy)	$4.11	A	425000	Acquired	2033-01-26	Common Stock (425000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	6563	Indirect
Common Stock	6563	Indirect
Common Stock	6563	Indirect

Footnotes

F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2022 through November 18, 2022. This transaction is also exempt under Rule 16b-3(c).

F2: The Purchase Period ended November 18, 2022 and is the sole Purchase Period in the Offering Period (as defined in the ESPP) that began May 18, 2022.

F3: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2022.

F4: Reflects Common Stock held by Irrevocable Trust of OSL held for the benefit of Dr. Litton's children.

F5: Reflects Common Stock held by Irrevocable Trust of SWL held for the benefit of Dr. Litton's children.

F6: Reflects Common Stock held by Irrevocable Trust of WGL held for the benefit of Dr. Litton's children.

F7: One thirty-sixth (1/36th) of the shares subject to the option will vest on February 27, 2023 and one thirty-sixth of the shares subject to the option will vest each month thereafter.